...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Coordination chemistry reviews >Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy
【24h】

Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy

机译：Control and utilization of ruthenium and rhodium metal complex excited states for photoactivated cancer therapy

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

The use of visible light to produce highly selective and potent drugs through photodynamic therapy (PDT) holds much potential in the treatment of cancer. PDT agents can be designed to follow an O_2-dependent mechanism by producing highly reactive species such as ~1O_2 and/or an O_2 independent mechanism through processes such as excited state electron transfer, covalent binding to DNA or photoinduced drug delivery. Ru(Ⅱ)-polypyridyl and Rh_2(Ⅱ,Ⅱ) complexes represent an important class of compounds that can be tailored to exhibit desired photophysical properties and photochemical reactivity by judicious selection of the ligand set. Complexes with relatively long-lived excited states and planar, intercalating ligands localize on the DNA strand and photocleave DNA through ~1O_2 production or guanine oxidation by the excited state of the chromophore. Photoinduced ligand substitution occurs through the population of triplet metal centered (~3MC) excited states and facilitates covalent binding of the metal complex to DNA in a mode similar to cisplatin. Ligand photodissociation also provides a route to selective drug delivery. The ability to construct metal complexes with desired light absorbing and excited state properties by ligand variation enables the design of PDT agents that can potentially provide combination therapy from a single metal complex.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号